Get started
Author

Sanne Lysbet de Haas

Promotion of sleep by targeting the orexin system in rats, dogs and humans
2007 · Catherine Brisbare-Roch, Jasper Dingemanse, et al. · Nature Medicine · 578
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
2020 · Leisha A Emens, Francisco J Esteva, et al. · The Lancet Oncology · 388
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
2016 · José Baselga, Gail D. Lewis Phillips, et al. · Clinical Cancer Research · 229
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
2013 · D W Miles, S L de Haas, et al. · British Journal of Cancer · 157
PDF
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA A α 2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers
2007 · S.L. de Haas, S.J. de Visser, et al. · Journal of Psychopharmacology · 104
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer
2016 · Sung‐Bae Kim, Hans Wildiers, et al. · International Journal of Cancer · 101
PDF
Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive, Locally Advanced, or Metastatic Breast Cancer
2014 · Kathy D. Miller, Véronique Diéras, et al. · Journal of Clinical Oncology · 85
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA A α 2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers
2006 · S.L. de Haas, S.J. de Visser, et al. · Journal of Psychopharmacology · 84
Orexin receptor antagonism: an ascending multiple-dose study with almorexant
2012 · Petra Hoever, Sanne L de Haas, et al. · Journal of Psychopharmacology · 71
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
2019 · Edith A. Perez, Sanne Lysbet de Haas, et al. · BMC Cancer · 67
PDF
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
2016 · M. Martin, P. Fumoleau, et al. · Annals of Oncology · 54
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
2019 · Manish A. Shah, Yoon-Koo Kang, et al. · Gastric Cancer · 53
PDF
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
2023 · Sanne L. de Haas, Dennis J. Slamon, et al. · Breast Cancer Research · 48
PDF
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
2022 · Sibylle Loibl, Chiun-Sheng Huang, et al. · npj Breast Cancer · 44
PDF
Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
2024 · Liang Huang, Da Pang, et al. · Nature Communications · 39
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
2022 · Chau Dang, Michael S. Ewer, et al. · Cancers · 23
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
2021 · Nadia Harbeck, Raquel von Schumann, et al. · Cancers · 17
PDF
MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers
2008 · J.D. Boot, S.L. De Haas, et al. · Pulmonary Pharmacology & Therapeutics · 9
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
2019 · Edith A. Perez, Sanne Lysbet de Haas, et al. · BMC Cancer · 5
PDF
1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
2011 · D.W. Miles, S.L. De Haas, et al. · European Journal of Cancer · 5
Abstract PD5-10: Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+ early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial
2020 · Claudia Biehl, Cornelia Kolberg-Liedtke, et al. · Cancer Research · 2
Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial
2026 · Luis E Lara González, Fabiola Giudici, et al. · The Lancet Oncology · 1
Local nitric oxide release does not affect tachyphylaxis to angiotensin II in dorsal hand veins in man in the presence of prostaglandin synthesis inhibition
2002 · S. L. de Haas, I. B. Wilkinson, et al. · British Journal of Clinical Pharmacology · 1
PDF
Peony exploratory analyses of biomarker changes: From baseline to surgical samples in patients with HER2+ breast cancer.
2024 · Chunzhe Duan, Da Pang, et al. · Journal of Clinical Oncology
Abstract PO2-11-06: Anti-Müllerian hormone in Young women with breast CAncer to predict permanent loss of ovarian function after chemotherapy and anti-HER2 therapy (AMYCA): a biomarker analysis of the BETH and KAITLIN trials
2024 · Matteo Lambertini, Deirdre Allegranza, et al. · Cancer Research
Works count: 34
Citation count: 2,165
H-index: 17
I10-index: 17
Year
Topic
Type